ARA-290 · Research brief

Can You Take ARA-290 Orally? (Bioavailability Explained)

Real Peptides Research TeamEditorial

Updated April 13, 20268 min read

53 WORDS

Short answer

Research-grade peptides face one universal constraint: digestive enzymes don't distinguish between dietary protein and pharmacologically active sequences. ARA-290, an 11-amino-acid peptide derived from erythropoietin's tissue-protective domain, degrades completely when exposed to gastric acid and proteolytic enzymes in the stomach and small intestine. Oral bioavailability approaches zero in every controlled study conducted to date.

Key takeaways

ARA-290 cannot be taken orally because gastric acid and digestive enzymes (pepsin, trypsin, chymotrypsin) cleave peptide bonds within 15–30 minutes, degrading the compound before it reaches systemic circulation.
Subcutaneous injection delivers 80–90% bioavailability by bypassing the gastrointestinal tract and first-pass hepatic metabolism, placing the peptide directly into interstitial fluid for capillary absorption.
Enteric-coated formulations delay gastric exposure but fail to prevent degradation by brush border peptidases (dipeptidyl peptidase-4, aminopeptidase N) in the small intestine.
ARA-290's molecular weight (approximately 1,200 Da) exceeds the paracellular permeability threshold (400–600 Da), preventing passive absorption across intestinal tight junctions even if the peptide survived enzymatic cleavage.
Reconstituted ARA-290 solutions must be stored at 2–8°C and used within 28 days; lyophilised powder stored at −20°C remains stable for 12–24 months before reconstitution.
Intranasal, sublingual, and transdermal routes are ineffective for ARA-290 due to the peptide's size, hydrophilicity, and lack of mucosal transport mechanisms.

We've worked with research facilities implementing peptide protocols across therapeutic categories for years. The question of oral delivery surfaces repeatedly because injection protocols require cold storage, sterile technique, and compliance barriers that oral dosing would eliminate. The mechanism of degradation, however, is non-negotiable. Peptide structure determines function, and gastric transit destroys that structure before the compound reaches receptor sites.

Can you take ARA-290 orally and achieve therapeutic plasma levels?

No. ARA-290 cannot be administered orally with any measurable bioavailability. Peptides containing more than 3–4 amino acids are degraded by pepsin, trypsin, and chymotrypsin in the gastrointestinal tract before they can cross the intestinal epithelium intact. Subcutaneous injection delivers the peptide directly into interstitial fluid, bypassing first-pass hepatic metabolism and enzymatic degradation, with bioavailability exceeding 80% in published pharmacokinetic studies. Oral administration results in complete peptide fragmentation within 15–30 minutes of ingestion.

The Featured Snippet answers whether oral dosing is viable. It isn't. What that block doesn't cover is why encapsulation, enteric coating, and liposomal formulations also fail for ARA-290 specifically. Enteric coatings delay gastric exposure but release the peptide into the small intestine, where brush border peptidases (aminopeptidases, dipeptidyl peptidase-4) complete the degradation pepsin began. Liposomal carriers protect against enzymatic cleavage but cannot facilitate transmucosal absorption of an 11-amino-acid sequence without receptor-mediated endocytosis. A mechanism ARA-290 does not trigger at intestinal mucosa. This article covers exactly why peptide structure dictates delivery method, what happens to ARA-290 during gastric transit, and why subcutaneous injection remains the only research-validated route.

Why ARA-290 Degrades in the Digestive Tract

Peptide bonds. The covalent linkages between amino acids in ARA-290's sequence. Are the primary substrate for digestive proteases. Pepsin, secreted in the stomach at pH 1.5–2.5, cleaves peptide bonds adjacent to aromatic amino acids (phenylalanine, tryptophan, tyrosine). ARA-290 contains multiple susceptible sites within its 11-residue structure. Once pepsin initiates fragmentation, trypsin and chymotrypsin in the duodenum complete the process, reducing the peptide to dipeptides and free amino acids within 20–40 minutes of oral ingestion.

Enteric-coated formulations attempt to bypass gastric degradation by releasing the payload at intestinal pH (6.5–7.5), but this strategy fails for two reasons. First, brush border enzymes (dipeptidyl peptidase-4, aminopeptidase N) expressed on enterocyte microvilli cleave peptides from the N-terminus and C-terminus simultaneously. A dual-directional attack that fragments even short sequences. Second, ARA-290's molecular weight (approximately 1,200 Da) exceeds the paracellular permeability threshold (400–600 Da) for passive absorption across tight junctions. Active transport mechanisms exist for dipeptides and tripeptides (PepT1 transporters), but 11-amino-acid sequences require receptor-mediated endocytosis. ARA-290 does not bind intestinal receptors capable of facilitating this process.

Subcutaneous injection places ARA-290 directly into the extracellular matrix of subcutaneous adipose tissue, where it diffuses into capillary beds without encountering digestive enzymes. Plasma half-life following subcutaneous administration ranges from 4–6 hours in pharmacokinetic studies, allowing sustained receptor occupancy at tissue-protective receptor sites (innate repair receptor, or IRR). Oral administration produces no detectable plasma concentration at any time point. The peptide never reaches systemic circulation intact.

Subcutaneous Injection as the Standard Delivery Method

Research protocols using ARA-290 universally specify subcutaneous injection at concentrations ranging from 1–4 mg per administration, typically dissolved in bacteriostatic water or sterile saline. Injection sites. Abdomen, thigh, upper arm. Provide access to subcutaneous adipose tissue with high capillary density, facilitating rapid absorption into systemic circulation. Bioavailability via this route exceeds 80%, meaning the majority of the injected dose reaches plasma in pharmacologically active form.

The injection process requires sterile technique: alcohol swab preparation of the injection site, use of insulin syringes (27–30 gauge, 0.5–1.0 mL capacity), and rotation of injection sites to prevent lipohypertrophy. Reconstituted peptide solutions stored at 2–8°C maintain stability for 28 days when prepared with bacteriostatic water containing 0.9% benzyl alcohol as a preservative. Lyophilised (freeze-dried) ARA-290 powder, stored at −20°C before reconstitution, remains stable for 12–24 months under proper conditions.

Our team has observed that researchers unfamiliar with peptide protocols often underestimate the precision required at the reconstitution stage. Injecting air into the vial while drawing solution creates positive pressure that can force particulate contaminants back through the needle on subsequent draws. The correct technique: insert the needle, draw the plunger to create negative pressure, then inject bacteriostatic water slowly down the vial wall (never directly onto the lyophilised cake). Swirl gently. Never shake. To dissolve the powder completely. Shaking denatures peptide bonds through mechanical shear stress.

Subcutaneous delivery also avoids first-pass hepatic metabolism. Oral drugs absorbed through intestinal epithelium enter the hepatic portal vein and pass through the liver before reaching systemic circulation. Hepatic enzymes (cytochrome P450 isoforms, peptidases) can metabolise the compound before it exerts systemic effects. Subcutaneous injection bypasses this pathway entirely, delivering ARA-290 directly to peripheral tissues without hepatic interference.

Alternative Delivery Methods and Why They Fail for ARA-290

Intranasal, sublingual, and transdermal delivery routes have been explored for other peptides. None are viable for ARA-290. Intranasal administration works for small lipophilic peptides (desmopressin, oxytocin analogues) that cross the nasal mucosa and enter the olfactory bulb or trigeminal nerve pathways. ARA-290's hydrophilic structure and 1,200 Da molecular weight prevent mucosal penetration. The compound remains in nasal secretions and is swallowed or expelled, leading to the same gastric degradation as oral dosing.

Sublingual delivery requires the peptide to diffuse across the oral mucosa into the submucosal capillary plexus. The sublingual route works for small molecules (nitroglycerin, buprenorphine) with molecular weights below 500 Da and high lipophilicity. ARA-290 is too large and too hydrophilic to cross stratified squamous epithelium. Sublingual placement results in swallowing the dissolved peptide, which then undergoes standard gastric degradation.

Transdermal patches deliver drugs through the stratum corneum via passive diffusion (fentanyl, nicotine) or iontophoresis (lidocaine). Peptides larger than 500 Da cannot penetrate intact skin. The lipid bilayers and keratinocyte structure form an impermeable barrier to hydrophilic macromolecules. Microneedle arrays and electroporation can breach the stratum corneum, but no commercial formulations exist for ARA-290, and research-scale systems remain cost-prohibitive for most applications.

The only experimentally validated alternative to subcutaneous injection is intravenous administration, which delivers 100% bioavailability by definition but requires trained personnel, sterile equipment, and vascular access. IV delivery is reserved for clinical settings. Research applications overwhelmingly use subcutaneous protocols due to simplicity and equivalent pharmacological outcomes.

Can You Take ARA-290 Orally?: Delivery Route Comparison

Delivery Route	Bioavailability	Onset Time	Stability Requirement	Practical Viability for Research	Professional Assessment
Oral (capsule, tablet)	0%. Complete peptide degradation by gastric and intestinal proteases before absorption	N/A. No systemic absorption	Requires enteric coating (ineffective due to brush border enzymes)	Not viable. No measurable plasma concentration at any dose	Oral administration of ARA-290 is pharmacologically futile; peptide structure cannot survive digestive transit
Subcutaneous injection	80–90%. Bypasses first-pass metabolism and enzymatic degradation	15–30 minutes to peak plasma concentration	Reconstituted solution: 2–8°C for 28 days; lyophilised powder: −20°C for 12–24 months	Standard method. Sterile technique required but achievable in research settings	Gold standard for ARA-290 delivery; proven bioavailability and consistent plasma levels
Intranasal spray	<5%. Limited mucosal absorption, majority swallowed and degraded	10–20 minutes (if any absorption occurs)	Same as subcutaneous	Not viable for ARA-290. Molecular weight and hydrophilicity prevent mucosal penetration	Intranasal route fails due to ARA-290's size and polarity; most peptide remains in nasal secretions
Sublingual tablet	<5%. Minimal oral mucosal penetration, degraded after swallowing	5–15 minutes (if absorbed)	Requires specially formulated tablet base	Not viable. No published data supporting sublingual bioavailability for ARA-290	Sublingual absorption requires lipophilicity ARA-290 lacks; swallowed fraction undergoes standard gastric degradation
Transdermal patch	0%. Stratum corneum impermeable to peptides >500 Da	N/A. No penetration	Requires microneedle or electroporation system (not commercially available)	Not viable without advanced delivery technology	Skin barrier prevents passive diffusion; microneedle systems remain experimental for peptides

What If: ARA-290 Administration Scenarios

What if I accidentally swallowed reconstituted ARA-290 instead of injecting it?

No systemic effect will occur. The peptide will be degraded in the stomach within 20–40 minutes. Gastric pH (1.5–2.5) and pepsin activity fragment the amino acid sequence into inactive peptides and free amino acids before any absorption can take place. The compound is not toxic when swallowed. It simply becomes pharmacologically inert. If this occurs, discard the swallowed dose as a loss and administer a fresh subcutaneous injection using a new aliquot from refrigerated stock. Document the error to avoid repeating it in future protocols.

What if I used an enteric-coated capsule to protect ARA-290 from stomach acid?

Enteric coating delays degradation but does not prevent it. The capsule releases ARA-290 in the small intestine at pH 6.5–7.5, where brush border enzymes (dipeptidyl peptidase-4, aminopeptidase N) cleave the peptide from both termini simultaneously. Even if a fraction survived enzymatic attack, the 1,200 Da molecular weight prevents passive absorption across enterocyte tight junctions. ARA-290 does not bind to PepT1 transporters (which handle dipeptides and tripeptides only) or trigger receptor-mediated endocytosis at intestinal mucosa. Plasma concentration remains undetectable regardless of enteric formulation.

What if I missed a scheduled subcutaneous dose — can I double the next injection?

No. Doubling doses increases the risk of injection site reactions (erythema, swelling, subcutaneous nodules) without proportionally increasing therapeutic benefit. ARA-290's half-life (4–6 hours) means plasma levels return to baseline within 24 hours of a missed dose. Resume the regular dosing schedule at the next planned interval rather than attempting to compensate. If doses are frequently missed, evaluate whether the injection schedule aligns with practical constraints. Adjusting frequency (e.g., from daily to every other day) with proportional dose adjustment may improve adherence without compromising research outcomes.

What if I stored reconstituted ARA-290 at room temperature overnight?

Peptide degradation accelerates significantly above 8°C. A single overnight temperature excursion (8–12 hours at 20–25°C) may reduce potency by 15–30%, but the solution is not necessarily worthless. If the vial was left out once, refrigerate it immediately and use it within 48 hours. Document the temperature excursion and consider it a compromised batch. If room-temperature storage exceeded 24 hours, or if the solution appears cloudy or discoloured, discard it entirely. Denatured peptides cannot be restored by refrigeration. The structural damage is irreversible.

The Unflinching Truth About Oral Peptide Delivery

Here's the honest answer: no formulation technology currently available can make ARA-290 orally bioavailable at meaningful levels. The marketing around

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

No. ARA-290 undergoes complete enzymatic degradation in the stomach and small intestine, resulting in zero systemic bioavailability when taken orally. Pepsin, trypsin, and chymotrypsin cleave the peptide bonds within 15–30 minutes of ingestion, fragmenting the 11-amino-acid sequence into inactive dipeptides and free amino acids before any absorption occurs. Subcutaneous injection is the only validated delivery route that maintains peptide structure and achieves measurable plasma concentrations.

Enteric coatings protect ARA-290 from gastric acid but release it into the small intestine, where brush border enzymes (dipeptidyl peptidase-4, aminopeptidase N) degrade the peptide from both termini. Even if enzymatic cleavage were prevented, ARA-290’s molecular weight (1,200 Da) exceeds the paracellular permeability threshold of 400–600 Da, preventing passive absorption across tight junctions. The peptide lacks the structural features required for active transport via PepT1 or receptor-mediated endocytosis at intestinal mucosa.

Subcutaneous injection places ARA-290 directly into the extracellular matrix of adipose tissue, bypassing the gastrointestinal tract and first-pass hepatic metabolism entirely. The peptide diffuses into subdermal capillaries without encountering digestive enzymes (pepsin, trypsin, chymotrypsin) or hepatic peptidases, achieving 80–90% bioavailability. Plasma half-life following subcutaneous administration is 4–6 hours, allowing sustained receptor occupancy at tissue-protective receptor sites.

Peptide stability degrades rapidly above 8°C. A single overnight temperature excursion (8–12 hours at 20–25°C) reduces potency by 15–30% due to thermal denaturation and oxidative degradation of susceptible amino acid residues. If the solution was left at room temperature for less than 24 hours, refrigerate it immediately and use within 48 hours — consider it a compromised batch and document the error. If room-temperature storage exceeded 24 hours, or if the solution appears cloudy or discoloured, discard it — denatured peptides cannot be restored by refrigeration.

No. Both routes are ineffective for ARA-290 due to molecular size and hydrophilicity. Intranasal delivery requires peptides smaller than 1,000 Da with lipophilic character to cross nasal mucosa — ARA-290 (1,200 Da, hydrophilic) remains in nasal secretions and is eventually swallowed or expelled. Sublingual absorption requires passive diffusion through oral mucosa, which excludes peptides larger than 500 Da — ARA-290 cannot penetrate stratified squamous epithelium and undergoes gastric degradation after being swallowed.

No. Swallowed ARA-290 is degraded into inactive amino acid fragments by gastric and intestinal enzymes — it is not toxic, merely pharmacologically inert. The peptide undergoes the same proteolytic breakdown as dietary protein, producing dipeptides and free amino acids that are absorbed and metabolised through normal pathways. The compound poses no toxicity risk when ingested orally; it simply fails to produce any therapeutic effect because it never reaches systemic circulation in intact form.

Reconstituted ARA-290 prepared with bacteriostatic water (0.9% benzyl alcohol) remains stable for 28 days when stored at 2–8°C in a sterile sealed vial. Peptide degradation accelerates beyond this timeframe due to oxidation of methionine residues and hydrolysis of peptide bonds, even under refrigeration. Lyophilised (freeze-dried) ARA-290 powder stored at −20°C before reconstitution maintains stability for 12–24 months. Once reconstituted, never refreeze the solution — freeze-thaw cycles cause irreversible aggregation and loss of activity.

Use a 27–30 gauge insulin syringe (0.5–1.0 mL capacity) to draw the reconstituted peptide solution from the vial. Swab the injection site (abdomen, thigh, or upper arm) with 70% isopropyl alcohol and allow it to dry for 30 seconds. Pinch the skin to create a subcutaneous fold, insert the needle at a 45–90 degree angle, aspirate briefly to confirm the needle is not in a vessel, then inject slowly over 5–10 seconds. Rotate injection sites to prevent lipohypertrophy — never inject into the same location two days in a row.

Peptides are inherently unstable compared to small-molecule drugs due to susceptibility to proteolytic cleavage, oxidation, aggregation, and deamidation. ARA-290 contains 11 amino acids linked by peptide bonds that hydrolyse spontaneously at neutral pH and accelerate under heat, light, or microbial contamination. Refrigeration (2–8°C) slows these degradation pathways, and bacteriostatic water suppresses bacterial growth that would otherwise produce enzymes capable of cleaving the peptide. Lyophilisation (freeze-drying) removes water, eliminating the solvent required for hydrolysis — this is why lyophilised powder can be stored long-term at −20°C.

No. Liposomal carriers protect peptides from enzymatic degradation but cannot facilitate absorption of an 11-amino-acid sequence across intestinal epithelium. ARA-290 lacks the receptor-binding domains required for receptor-mediated endocytosis at enterocyte membranes, and its molecular weight (1,200 Da) prevents paracellular diffusion through tight junctions. Liposomes may delay degradation temporarily, but the peptide still cannot cross into systemic circulation — published studies show no measurable plasma concentration of ARA-290 following oral liposomal administration at any dose tested.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA